What is retatrutide?
Retatrutide is an experimental weight-loss drug that, as of 2026, had not yet reached the market. The material tracks its emergence as an anticipated next-generation obesity treatment and the early, informal use of related peptides ahead of its release.
Release history
- Apr 2026 - Dr Alex Tatem described retatrutide as “the next blockbuster drug that Lilly is going to come out with probably in the next couple of months.”
- Jul 2026 - Andrew Huberman said most people taking these peptides are not gym-going men but women seeking a low-dose version of retatrutide, which “is not out yet.”
- Sep 2026 - Huberman said people lost approximately one-third of their body weight in about a year or so.
In the discourse
Attributed discussion of retatrutide.
The GLP-1 drug retatrutide produced approximately one-third body-weight loss in roughly one year of use.
“People lost onethird approximately of their body weight in about a year or so.”Andrew Huberman · 3 Sep 2026
Retatrutide (Eli Lilly) is expected to launch within months and has already been adopted by bodybuilders as a standard cutting-protocol compound, sourced from research-use-only sites for roughly two years.
“The next blockbuster drug that Lilly is going to come out with probably in the next couple of months is this guy called retatrutide.”Dr Alex Tatem · 20 Apr 2026
Retatrutide is the GLP-class compound most sought by women in the peptide market even before FDA approval, making it a high-demand drug to track through approval.
“Most people taking these peptides are not gymgoing guys. It's women who want to take a lowd dose reetta, but rea is not out yet.”Andrew Huberman · 22 Jul 2026
Huberman on who actually uses peptides, pushing back on the gym-bro stereotype.
“Most people taking these peptides are not gymgoing guys. It's women who want to take a lowd dose reetta, but rea is not out yet.”Andrew Huberman · 22 Jul 2026